Trillium Therapeutics Inc. (Trillium), formerly Stem Cell Therapeutics Corp., is a Canada-based immuno-oncology company developing therapies for the treatment of cancer. The Company's lead program, SIRPaFc, is an antibody-like protein that harnesses the innate immune system by blocking the activity of CD47, a molecule whose expression is increased on cancer cells to evade the host immune system. SIRPaFc is in pre-clinical development as a treatment for acute myeloid leukemia (AML). CD47 binds SIRPaFc on the surface of macrophages, and transmits a do-not-eat signal that protects cells from macrophage attack. The Company is also developing human monoclonal antibodies that block the activity of CD200, an immunosuppressive molecule. The Company's antibodies bind to human CD200 with high affinity, potently neutralize CD200 function in-vitro, and have anti-tumor activity in a human xenograft model.